At the news
? MIXEDIMPACT 5/10 PRESS-RELEASE filed May 6, 2026 at 16:00 ET
Arcutis Biotherapeutics reported Q1 2026 net product revenue of $105.4M (+65% YoY), beating consensus of $103.7M, but EPS of -$0.09 missed consensus of -$0.06. Full-year 2026 revenue guidance of $480M-$495M was maintained. The stock may face pressure from the EPS miss despite strong revenue growth and positive operating cash flow.
- Q1 2026 net product revenue $105.4M, +65% YoY vs $63.8M, beating $103.7M consensus
- GAAP EPS -$0.09 vs consensus -$0.06 (miss of 50%)
- Full-year 2026 revenue guidance maintained at $480M-$495M
- Positive operating cash flow of $2.2M in Q1 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access